Influenza is a highly contagious viral disease, which is primarily spread through water droplets containing strains of the virus. Dr Leong Chee Loon shares his insights into the management of influenza in Malaysia, highlighting the importance of improving vaccination coverage in populations at high-risk of influenza-related complications, such as elderly patients and healthcare practitioners.
At the 13th Asian Congress of Paediatric Nephrology 2017 in conjunction with the 39th Malaysian Paediatric Association Annual Congress, Dr Wanatpreeya Phongsamart spoke on the importance of influenza vaccination in children, highlighting the role of quadrivalent influenza vaccine (QIV) in providing a broader protection against influenza. Meanwhile, Emeritus Professor Somsak Lolekha shared his insights into the effectiveness of a hexavalent vaccine in paediatric immunization, and discussed its role in the Malaysian paediatric immunization schedule.
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia.
At the recent Asia Pacific Alliance for the Control of Influenza (APACI) workshop in Kuala Lumpur, MIMS Doctor had the privilege of having an exclusive interview with eminent paediatric infectious disease specialist, Associate Professor Tawee Chotpitayasunondh. This article captures the highlights from our conversation with him.
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
The Asia Pacific Alliance for the Control of Influenza (APACI) recently organized an influenza workshop in Kuala Lumpur. The workshop saw eminent speakers from seven countries presenting on topics concerning the impact of influenza, vaccination of various populations, current and upcoming treatments for influenza, policy considerations and approaches for pandemic preparedness. Read about highlights from the workshop in this newsletter.
It is safe to revaccinate patients with a history of mild or moderate adverse events following immunization (AEFI), but more research is required in those with serious AEFIs who are less likely to be reimmunized, suggests a recent study.